Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia

Bone Marrow Transplantation

Volumn 37, Issue 11, 2006, Pages 997-1001

  Trifilio, S ^a,b   Gordon, L ^b   Singhal, S ^b   Tallman, M ^b   Evens, A ^b   Rashid, K ^b   Fishman, M ^b   Masino, K ^b   Pi, J ^a   Mehta, J ^b  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Hyperuricemia; Rasburicase; Tumor lysis syndrome; Uric acid

Indexed keywords

ALLOPURINOL; ANTINEOPLASTIC AGENT; CREATININE; MELPHALAN; RASBURICASE; URIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FLUID THERAPY; HEMATOLOGIC MALIGNANCY; HEMODIALYSIS; HUMAN; HYPERURICEMIA; KIDNEY FAILURE; MALE; MYELODYSPLASTIC SYNDROME; MYELOMA; NONHODGKIN LYMPHOMA; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; URIC ACID BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; CREATININE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; NEOPLASMS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TUMOR LYSIS SYNDROME; URATE OXIDASE; URIC ACID;

EID: 33646799491     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705379     Document Type: Review

References (13)

1. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 2004; 116: 546-554.
2. Smith GW, Wright V. Allopurinol. Br J Clin Pract 1987; 41: 710-711.
3. Wu XW, Lee CC, Muzny DM, Caskey CT. Urate oxidase: Primary structure and evolutionary implications. Proc Natl Acad Sci USA 1989; 86: 9412-9416.
4. Leach M, Parsons RM, Reilly JT, Winfield DA. Efficacy of urate oxidase (uricozyme) in tumour lysis induced urate nephropathy. Clin Lab Haematol 1998; 20: 169-172.
5. Bayol A, Capdevielle J, Malazzi P, Buzy A, Bonnet MC, Colloc'h N et al. Modification of a reactive cysteine explains differences between rasburicase and uricozyme, a natural Aspergillus flavus uricase. Biotechnol Appl Biochem 2002; 36: 21-31.
6. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001; 97: 2998-3003.
7. Coiffier B, Mounier N, Bologna S, Fermé C, Tilly H, Sonet A et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: Results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003; 21: 4402-4406.
8. Lee AC, Li CH, So KT, Chan R. Treatment of impending tumor lysis with single-dose rasburicase. Ann Pharmacother 2003; 37: 1614-1617.
9. Hummel M, Buchheidt D, Reiter S, Bergmann J, Hofheinz R, Hehlmann R. Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome. Leukemia 2003; 17: 2542-2544.
10. Trifilio S, Tallman M, Singhal S, Gordon L, Evens A, Mehta J. Low-dose recombinant urate oxidase (rasburicase) is effective in hyperuricemia. Blood (ASH Annu Meeting Abstr) 2004; 104: 3312.
11. Annemans L, Moeremans K, Lamotte M, Garcia Conde J, van den Berg H, Myint H et al. Pan-European multicentre economic evaluation of recombinant orate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Suppl Care Cancer 2003; 11: 249-257.
12. Wossmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/ leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 2003; 82: 160-165.
13. Schrag D. The price tag on progress - chemotherapy for colorectal cancer. N Engl J Med 2004; 351: 317-319.